HER2 Therapies in Non-Small Cell Lung Cancer (NSCLC).

Abstract excerpt

This review discusses the role of human epidermal growth factor receptor 2 (HER2/ERBB2) as a key oncogenic driver in non-small cell lung cancer (NSCLC), including exon 20 activating mutations, gene amplification, and protein overexpression. These forms differ in their biological effects and predictive value, but HER2 mutations, especially exon 20 insertions, are the primary oncogenic mechanism. Regarding...

Topics

Join the communities discussing this publication.

• Carcinoma, Non-Small-Cell Lung
• Erb-b2 Receptor Tyrosine Kinases
• ERBB2 gene
• NRG1 gene
• Lung Neoplasms